Full text is available at the source.
Current clinical application of incretin therapy for obesity management
Using Incretin Therapy to Treat Obesity in Current Medical Practice
AI simplified
Abstract
Incretin therapy may significantly promote weight reduction through appetite suppression and metabolic improvements.
- Glucagon-like peptide-1 (GLP-1) receptor agonists and dual receptor agonists are central to obesity management.
- Liraglutide, semaglutide, and tirzepatide are associated with decreased caloric intake.
- Recent studies indicate that semaglutide and tirzepatide may achieve substantial weight loss beyond just lowering glucose levels.
- Challenges regarding long-term efficacy, tolerability, and accessibility of these therapies remain.
- Future efforts could focus on optimizing combination therapies and developing new incretin-based molecules with additional receptor activity.
AI simplified